Indeed, it seems like the mRNA vaccines got tons of traction because of a combination of high efficacy and first-mover advantage, but protein subunit vaccines l

Indeed, it seems like the mRNA vaccines got tons of traction because of a combination of high efficacy and first-mover advantage, but protein subunit vaccines like Novavax's (which unfortunately has taken forever to get to market) seem to be comparably efficacious, don't have the crazy cold-chain requirements, and depend on technologies that are much more broadly understood (adjuvanted protein subunit vaccines for other diseases are already available as generics manufactured in developing-world facilities). It seems like something like that would be a better reverse-engineering starting point.